| Literature DB >> 30768369 |
Mohamad Bassam Sonbol1, Daniel H Ahn1, David Goldstein2, Takuji Okusaka3, Josep Tabernero4, Teresa Macarulla5, Michele Reni6, Chung-Pin Li7,8, Bert O'Neil9, Eric Van Cutsem10, Tanios Bekaii-Saab1.
Abstract
Napabucasin (also known as BBI-608 or BBI608) is an investigational, oral agent hypothesized to inhibit multiple oncogenic pathways. In this article, we describe the design and rationale for the CanStem111P clinical trial, a multicenter, randomized, open-label, Phase III study designed to determine the efficacy and safety of combining napabucasin with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma (NCT02993731). Patients were randomized in a 1:1 fashion to receive weekly gemcitabine and nab-paclitaxel with or without napabucasin. The results of this study will help define the role of this novel agent in the management of advanced pancreatic cancer.Entities:
Keywords: BBI-608; CanStem111P; cancer stem cells; napabucasin; pancreatic adenocarcinoma
Mesh：
Substances：
Year: 2019 PMID： 30768369 DOI： 10.2217/fon-2018-0903
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404